IRIS
PUGLISI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.263
AS - Asia 12.050
EU - Europa 7.352
SA - Sud America 2.235
Continente sconosciuto - Info sul continente non disponibili 1.407
AF - Africa 274
OC - Oceania 17
Totale 52.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.556
SG - Singapore 5.765
CN - Cina 2.300
BR - Brasile 1.757
IT - Italia 1.679
UA - Ucraina 1.281
HK - Hong Kong 1.176
VN - Vietnam 1.064
DE - Germania 961
RU - Federazione Russa 604
FI - Finlandia 581
FR - Francia 526
CA - Canada 371
GB - Regno Unito 370
SE - Svezia 358
IN - India 353
BD - Bangladesh 347
IE - Irlanda 321
TR - Turchia 201
AR - Argentina 157
KR - Corea 150
NL - Olanda 105
MX - Messico 97
PL - Polonia 90
JP - Giappone 88
AT - Austria 83
EC - Ecuador 79
ID - Indonesia 77
IQ - Iraq 76
CO - Colombia 74
ZA - Sudafrica 68
ES - Italia 62
BE - Belgio 59
PK - Pakistan 58
VE - Venezuela 57
CZ - Repubblica Ceca 44
SA - Arabia Saudita 44
JM - Giamaica 42
LT - Lituania 40
CH - Svizzera 39
CR - Costa Rica 35
MA - Marocco 34
UZ - Uzbekistan 34
RO - Romania 32
AE - Emirati Arabi Uniti 31
CL - Cile 31
IR - Iran 31
TG - Togo 30
HN - Honduras 28
PY - Paraguay 27
IL - Israele 25
PH - Filippine 25
TN - Tunisia 24
PE - Perù 22
TT - Trinidad e Tobago 22
GR - Grecia 21
KE - Kenya 21
EG - Egitto 20
NP - Nepal 20
DZ - Algeria 19
GT - Guatemala 19
UY - Uruguay 19
MY - Malesia 18
TH - Thailandia 18
NI - Nicaragua 17
EU - Europa 16
SV - El Salvador 16
AU - Australia 15
OM - Oman 15
EE - Estonia 14
KZ - Kazakistan 14
AL - Albania 12
AZ - Azerbaigian 12
BO - Bolivia 12
JO - Giordania 12
CW - ???statistics.table.value.countryCode.CW??? 11
LB - Libano 11
KG - Kirghizistan 10
PR - Porto Rico 10
AM - Armenia 9
ET - Etiopia 9
LV - Lettonia 9
PS - Palestinian Territory 9
DK - Danimarca 8
DO - Repubblica Dominicana 8
RS - Serbia 8
TW - Taiwan 8
BB - Barbados 7
BG - Bulgaria 7
BY - Bielorussia 7
PA - Panama 7
SC - Seychelles 7
GP - Guadalupe 6
LA - Repubblica Popolare Democratica del Laos 6
BH - Bahrain 5
CI - Costa d'Avorio 5
KH - Cambogia 5
MD - Moldavia 5
MN - Mongolia 5
NO - Norvegia 5
Totale 51.108
Salva come PNG Salva come JPEG
Città #
Ashburn 2.827
Fairfield 2.564
Singapore 2.347
Woodbridge 1.762
San Jose 1.628
Houston 1.306
Council Bluffs 1.279
Hong Kong 1.164
Chandler 1.120
Seattle 1.021
Ann Arbor 1.010
Beijing 979
Wilmington 934
Cambridge 856
Jacksonville 821
Los Angeles 589
Boardman 566
Dearborn 549
Chicago 513
Lauterbourg 384
Ho Chi Minh City 327
Dublin 309
New York 307
Santa Clara 306
Princeton 299
Dallas 246
Buffalo 224
Hanoi 217
Milan 204
Udine 192
Hefei 186
São Paulo 180
Salt Lake City 175
Phoenix 166
Helsinki 165
Munich 158
San Diego 148
The Dalles 146
Dong Ket 145
Redondo Beach 136
Seoul 134
Izmir 126
North Bergen 112
Rome 98
Tampa 98
Elk Grove Village 94
Des Moines 88
Frankfurt am Main 88
Ogden 86
Brooklyn 84
Tokyo 83
Denver 80
Nuremberg 80
Montreal 79
Toronto 75
Warsaw 75
Orem 70
Atlanta 62
Miami 61
Ottawa 57
Brussels 53
Lancaster 53
Washington 53
London 52
Norwalk 51
Guangzhou 50
Naples 49
Stockholm 48
Turku 47
Chennai 45
Mumbai 45
Nanjing 45
Sterling 44
Trieste 43
Detroit 42
Kunming 42
Mexico City 41
Rio de Janeiro 39
San Francisco 39
Amsterdam 38
Baghdad 38
Belo Horizonte 38
Poplar 38
Da Nang 37
Johannesburg 37
Brasília 36
Codroipo 36
Boston 34
Lappeenranta 34
Manchester 34
Newark 34
Vienna 34
Charlotte 33
Shanghai 33
Paris 32
Curitiba 30
Lomé 30
Tashkent 30
Bologna 29
Brno 29
Totale 31.780
Salva come PNG Salva come JPEG
Nome #
Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype 692
Risks in Oncology and Radiation Therapy 691
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 488
Hepatitis B and cancer: A practical guide for the oncologist 283
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress 239
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 238
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects 237
Bone scanning in lung cancer [2] (multiple letters) 237
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 230
Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? 218
Expression of periostin in human breast cancer 216
Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value 216
Role of pre-surgical breast MRI in the management of invasive breast carcinoma 211
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 206
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 204
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers 203
Pattern of metastasis and outcome in patients with breast cancer 202
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 201
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 198
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 197
Galectin-3 expression in non-small cell lung carcinoma 196
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 196
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 194
Role of mammography, ultrasound and large-core biopsy in the diagnostic evaluation of papillary breast lesions 192
BRCA2 GERMLINE MUTATIONS IN PRIMARY CANCER OF THE FALLOPIAN TUBE 192
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells 191
Bevacizumab in older patients with advanced colorectal or breast cancer 190
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 190
B-cell lymphoma presenting as acute pancreatitis 189
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 189
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer 188
Molecular diagnosis of neoplasms 187
Taxane-induced nail changes: incidence, clinical presentation and outcome 185
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 184
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 183
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 182
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. 181
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 181
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. 180
D-dimer and venous thromboembolism 179
Bone scanning in lung cancer: pretest probability is of value 179
Gene expression profiling in breast cancer: a clinical perspective. 179
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 176
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy 175
Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) 174
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 174
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 173
Primary therapy in breast cancer: what have we learned from landmark trials? 173
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer 171
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 171
What does similarity mean in clinical trials? 170
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 170
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 169
[Early breast cancer in pre-menopausal women and endocrine treatment: which factors impact on decision-making process?] 169
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients 169
LOCALLY ADVANCED BREAST CANCER: COMPARISON OF MAMMOGRAPHY, SONOGRAPHY AND MR IMAGING IN EVALUATION OF RESIDUAL DISEASE IN WOMEN RECEIVING NEOADJUVANT CHEMOTHERAPY 169
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer 167
Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study 167
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 167
Novel De Novo BRCA2 Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway 166
TSH controls ref-1 nuclear translocation in thyroid cells 166
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer 165
Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma 165
Predictors of axillary lymph node metastases in patients with T1 breast carcinoma 165
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 165
Atypical ductal hyperplasia of the breast. Its diagnostic imaging and the role of percutaneous needle biopsy with a 14-gauge needle 164
Prognostic evaluation in palliative care: final results from a prospective cohort study 163
Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? 163
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 163
Expert pathology consultation through the Internet: melanoma versus benign melanocytic tumours 162
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 162
Do platinum salts fit all triple negative breast cancers? 162
p53 protein expression and p53 mutation in thymic epithelial tumors 161
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly 161
Angiogenesis and tumor growth 160
Treatment of HER2-positive breast cancer: current status and future perspectives 159
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 159
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 158
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 158
Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology 157
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. 157
Information to cancer patients: a questionnaire survey in three different geographical areas in Italy. 157
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients 156
Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas 156
Looking for predictive markers in breast cancer 156
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 156
First-line chemotherapy with or without biologic agents for metastatic breast cancer 155
PROTEOMIC EVALUATION OF CORE BIOPSY SPECIMENS FROM BREAST LESIONS 155
FEASIBILITY STUDY OF A WEB APPLICATION FOR SELF-REPORT OF ANTICANCER TREATMENT TOXICITIES 155
MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index 155
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial 155
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 155
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 155
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly? 154
Capecitabine-induced cardiotoxicity: More evidence or clinical approaches to protect the patients' heart? 154
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report 153
Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors 153
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 153
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 152
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. 152
Totale 19.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 198.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.880 0 0 0 0 69 142 148 116 40 440 551 374
2022/20232.662 332 191 71 309 270 726 29 205 338 37 90 64
2023/20241.387 123 91 73 51 194 277 41 74 134 109 59 161
2024/20257.555 190 466 304 251 377 416 470 430 768 706 1.191 1.986
2025/202617.102 1.641 2.326 1.454 1.607 2.241 1.204 1.746 607 1.143 1.263 1.174 696
2026/20275.778 549 1.365 1.558 2.260 46 0 0 0 0 0 0 0
Totale 52.598